- Coordinator
- Meletios Therapeutics, France
- Runs
- 1 January 2023 to 31 December 2024
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190144923
What the project is doing
In the project's own words, from its summary on CORDIS.
Founded in 2020, Meletios is developing innovative antiviral strategies to treat existing and emerging acute viral infections. Among those, our lead program, presented at the EIC Accelerator, is an oral Host-Directed Agent targeting cell mechanisms hijacked by viruses. By acting on cell membranes fluidity, our antiviral strongly limits cell internalization and intracellular trafficking of viruses. This approach could be effective against broad virus families, conferring our molecule with an advantageous broad-spectrum effect, a key strategy to boost our capacities to ward off outbreaks.
Moreover, our agent has immunomodulatory effects enabling to efficiently manage viral diseases by preventing excessive immune system reactions. We will perform an accelerated development process as our molecule has already proved it safety in humans. COVID-19 will be the first demonstrator of our molecules efficacy, before targeting diseases induced by other coronaviruses, influenza, flaviviruses.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Meletios Therapeutics | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI